Article Versions Notes

Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S, Bargou R, Kübler H, et al. miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. Journal of Clinical Medicine. 2020; 9(3):670. https://doi.org/10.3390/jcm9030670

Krebs, Markus, Antonio Giovanni Solimando, Charis Kalogirou, André Marquardt, Torsten Frank, Ioannis Sokolakis, Georgios Hatzichristodoulou, Susanne Kneitz, Ralf Bargou, Hubert Kübler, and et al. 2020. "miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro" Journal of Clinical Medicine 9, no. 3: 670. https://doi.org/10.3390/jcm9030670

Krebs, M., Solimando, A. G., Kalogirou, C., Marquardt, A., Frank, T., Sokolakis, I., Hatzichristodoulou, G., Kneitz, S., Bargou, R., Kübler, H., Schilling, B., Spahn, M., & Kneitz, B. (2020). miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. Journal of Clinical Medicine, 9(3), 670. https://doi.org/10.3390/jcm9030670